A company has entered into a non-clinical evaluation agreement with NIAID, partnering with AFRRI on protocol design that meets FDA Animal Rule criteria.
3 reports, 2 independent
Updated Aug 12
Gone quiet
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A company has entered into a non-clinical evaluation agreement with NIAID, partnering with AFRRI on protocol design that meets FDA Animal Rule criteria.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
National Institute of Allergy and Infectious Diseases
US research institute for the treatment and prevention of infectious diseases
-
Armed Forces Radiobiology Research Institute
joint American military radiobiology research institution
Nothing else this week.
- FDA
-
company
legal entity representing an association of people, whether natural, legal or a mixture of both, with a specific objective
Related events
- A clinical study led by Dr. Swee Lay Thein is underway at the National Institutes of Health and is subject to oversight by the Food and Drug Administration.
- Iovance Biotherapeutics received FDA approval for its therapy, and the company is listed on Nasdaq.
- A supply deal for NUBEQA was finalized between ORIC Pharmaceuticals and BAYER after talks with the FDA.
- A product, NitroMist®, requires FDA approval for sale, and distributor access is being established for federal supply channels.
- FDA approval supports commercial partner contracts for Vericel.